Olukemi Ajayi Olugemo (Ajayi), MD

Unless otherwise indicated, this information has been self-reported and has not been verified by the Board of Medicine.

None Reported

None Reported

Pharmacokinetic properties and tolerability of low-dose SoluMatrix diclofenac
Clin Ther
Volume: 37
Date: 02 2015
https://www.ncbi.nlm.nih.gov/pubmed/25499666

Pharmacokinetics and safety of low-dose submicron indomethacin 20 and 40 mg compared with indomethacin 50 mg
Postgrad Med
Volume: 127
Date: 03 2015
https://www.ncbi.nlm.nih.gov/pubmed/25639879

CROs and CNS research: challenges and trends
Drug Discovery Today
Volume: 23
Date: 06 2018
https://www.sciencedirect.com/science/article/pii/S1359644618300345?via%3Dihub

ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable
Orphanet J Rare Dis
Volume: 16
Date: 05 2021
pubmed.ncbi.nlm.nih.gov/33957949/

Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update
J Neurol
Volume: 12
Date: 12 2022
pubmed.ncbi.nlm.nih.gov/35908242/

Conducting CNS trials during a public health emergency – Lessons learned from the COVID-19 pandemic: A joint ISCTM/ECNP working group consensus paper
Neuroscience Applied
Volume: 2
Date: 06 2023
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10275769/